Figure 4.

ABTL0812 treatment induces TRIB3 and DDIT3 mRNA levels in blood from patients enrolled in phase 2 clinical trial (NCT03366480). (a) Blood TRIB3 and DDIT3 mRNA levels from patients enrolled in phase 2 clinical trial (N = 14 for TRIB3; N = 12 for DDIT3). Values represented in the scatter plot correspond to the mean ± SEM of 2^−△△Ct values. Values show fold-changes of mRNA levels, referred to as “0” value. (b) Whole blood TRIB3 and DDIT3 mRNA levels of nine patients before (0) or after 1,300 mg t.i.d. ABTL0812 oral daily treatment as monotherapy (8 h and 7 d) or in combination with chemotherapy (28 d). mRNA levels were evaluated by RT-qPCR. Each value is the mean ± SD of three technical replicates. Patients 6 and 7 showed increased TRIB3 mRNA levels only, whereas patients 8 and 9 showed increased DDIT3 mRNA levels only. Values show fold-changes of mRNA levels, referred to as “0” value. Statistical analyses were performed using the △△Ct values. A one-way ANOVA Tukey test was applied. *, P < 0.05; **, P < 0.005; ***, P < 0.001 compared to day 0 sample